| Clone | 5C5 |
| Isotype | IgM |
| ProductType | PrimaryAntibodies |
| Units | 5ml |
| Host | Mouse |
| Application | Immunohistochemistry(frozen)Immunohistochemistry(paraffin) |
BackgroundTheantibody5C5whichisdirectedagainstsarcomericalpha-actinlabelsskeletalandheartmusclecellsbutnotsmoothmusclecells.InneoplasmsitmaybeusedasaMarkerofrhaBDomyosarcoma.Movementofcellorganelles,cells,andorganismsdependsontheinteractionofthecytoskeletalproteinsactinandmyosin.Inbirdsandmammalsuptonowsixdifferentisoformsofactinhavebeenidentifiedusingaminoacidsequenceanalysisandelectrophoresis.Theyaremoreorlessspecificfordifferentorgansresp.celltypes.Fourisoformsareknowntooccurinmusclecells,whiletwootherformsarefoundinmostothercelltypes.Alpha-Actinsarcomeric(a-sr-1)specificforskeletal-andheart-muscle.
Source
Immunogen:Purifiedrabbitskeletalmuscleactin
ProductAntibodysolutioninstABIlizingphosphatebufferpH7.3.Contains0.09%sodiumazide**.Thevolumeissufficientforatleast50immunohistochemicaltests(100µlworkingsolution/test).Useappropriateantibodydiluente.g.BIOLOGOArt.No.PU002,iffurtherdilutionisrequired.
PurificationMethod:AntibodysolutioninstabilizingphosphatebufferpH7.3.Contains0.09%sodiumazide**.Thevolumeissufficientforatleast50immunohistochemicaltests(100µlworkingsolution/test).Useappropriateantibodydiluente.g.BIOLOGOArt.No.PU002,iffurtherdilutionisrequired.
SecondaryReagents:Assecondaryreagentswerecommendtheuseofbiotinylatedanti-mouseIgMantibody(Art.No.BA-2020)incombinationwithstreptavidinconjugatesorABCsystems.
Specificity
SpeciesReactivity:Human,amphibia,bonyfish,cattle,guineapig,reptiles,rabbit,rat,sheep
ApplicationsIHC(C,P)
IncubationTime:60minatRT
WorkingConcentration:(RTU)neat
Pre-Treatment:Noproteasepre-treatmentnecessary.BlockingofendogenoUSPeroxidaseandalkalinephosphataserecommendeddependingonthedetectionsysteminuse.
PositiveControl:Skeletalmuscle
Storage2-8°C
CautionThisproductisintendedFORRESEARCHUSEONLY,andFORTESTSINVITRO,notforuseindiagnosticortherapeuticproceduresinvolvinghumansoranimals.Itmaycontainhazardousingredients. PleaserefertotheSafetyDataSheets(SDS)foradditionalinformationandproperhandlingprocedures.Disposeproductremaindersaccordingtolocalregulations.Thisdatasheetisasaccurateasreasonablyachievable,butNordic-Mubioacceptsnoliabilityforanyinaccuraciesoromissionsinthisinformation.
References1.SkalliO,GabbianiG,BabaiF,SeemayerTA,PizzolatoG,SchurchW.Intermediatefilamentproteinsandactinisoformsasmarkersforsofttissuetumordifferentiationandorigin.II.Rhabdomyosarcomas.Am.J.Pathol.,130;515ff(1988)2.BabaiF,SkalliO,SchurchW,SeemayerTA,GabbianiG.Chemicallyinducedrhabdomyosarcomasinrats.Ultrastructural,immunohistochemical,biochemicalfeaturesandexpressionofalpha-actinisoforms.VirchowsArchBCellPatholInclMolPathol.1988;55(5):263-77.3.HasegawaT,MatsunoY,NikiT,HirohashiS,ShimodaT,TakayamaJ,WatanabeC,KanekoA,SanoT,SatoM,SuzukiJ.Secondprimaryrhabdomyosarcomasinpatientswithbilateralretinoblastoma:aclinicopathologicandimmunohistochemicalstudy.AmJSurgPathol.1998Nov;22(11):1351-60.4.EusebiV,DamianiS,PasquinelliG,LorenziniP,ReuterVE,RosaiJ.Smallcellneuroendocrinecarcinomawithskeletalmuscledifferentiation:reportofthreecases.AmJSurgPathol.2000Feb;24(2):223-30.Review.5.TornoczkyT,KalmanE,SapiZ,OroszZ,PajorL.Cytogeneticabnormalitiesofalveolarsoft-partsarcomasusinginterphasefluorescentinsituhybridization:trisomyforchromosome7andmonosomyforchromosomes8and18seemtobecharacteristicofthetumor.VirchowsArch.2001Feb;438(2):173-80.
ProteinReference(s)
DatabaseName:UniProt
Accessionnumber:P68133(ACTS_HUMAN)
SpeciesAccession:Human
SafetyDatasheet(s)forthisproduct:NM_SodiumAzide/wp-content/uploads/SDS/AntibodySDSwithSodiumAzideNoridic-MUbio.pdf
